Sandoz is introducing ferumoxytol injection.
The product is the generic of AMAG Pharmaceuticals’ Feraheme (ferumoxytol injection).
It is used to treat iron deficiency anemia in adult patients who have an intolerance to oral iron or have had an unsatisfactory response to oral iron, or who have chronic kidney disease.
The overall IV iron market is over a one billion dollar market and continues to grow, the company said.
“As the first generic high dose IV iron available in the United States, ferumoxytol provides patients with iron deficiency anemia a more cost-effective treatment option,” said Keren Haruvi, Sandoz president. “This launch delivers on our strategy to continue to build our hospital and clinic portfolio and provide U.S. patients access to affordable generic medicines that work as well as brand-name products.”
Sandoz initially plans to make this medicine available to patients in the hospital and clinic setting.